A Phase II study of LP-003, a novel high-affinity, long-acting anti-IgE antibody for allergic rhinitis

Allergic rhinitis (AR) is a common IgE-mediated disorder that affects large population worldwide. Omalizumab was the only approved anti-IgE antibody for several allergic diseases. However, due to Omalizumab's dosing regimen and high price, its application in AR is strictly limited. Thus, a new anti-IgE antibody with better efficacy, lower dosing, longer half-life and competitive pricing and compliance is worth to be investigated.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research